Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Your review * Your review * Great service
When stratified by comparator groups, the pooled estimate was most favorable in monotherapy trials versus placebo (SMD 2.41, 95% CI 4.43 to 0.39), whereas the add-on designs versus the same background treatment (SMD 0.65, 95% CI 1.85 to 0.55), head-to-head comparisons versus another drug (SMD 0.19, 95% CI 0.84 to 0.45), and add-on designs versus placebo (SMD 0.65, 95% CI 1.35 to 0.06) showed more modest estimates and did not provide clear evidence of a between-group difference overall (p=0.21)
Eur J Criminol Neurol
Research suggests specific strains have documented roles in metabolic health and GLP-1 production mechanisms: Akkermansia muciniphila has emerged as one of the most extensively researched bacterial strains for metabolic health, earning designation as a "next-generation probiotic" in scientific literature
US$ 25.32
US$ 23.86
US$ 28.71
US$ 29.53
US$ 21.88
US$ 28.78
